206,499 Shares in Haleon plc (NYSE:HLN) Bought by Callan Family Office LLC

Callan Family Office LLC acquired a new position in Haleon plc (NYSE:HLN) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 206,499 shares of the company’s stock, valued at approximately $1,970,000.

A number of other large investors have also recently bought and sold shares of HLN. FMR LLC boosted its holdings in Haleon by 5.8% in the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after purchasing an additional 5,768,117 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Haleon in the fourth quarter worth $42,193,000. Wellington Management Group LLP boosted its holdings in Haleon by 49.9% in the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after purchasing an additional 3,046,841 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Haleon by 25.3% in the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. Finally, Natixis Advisors LLC boosted its holdings in Haleon by 142.5% in the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after purchasing an additional 866,070 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Stock Up 0.5 %

NYSE HLN opened at $10.45 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The firm has a 50-day simple moving average of $9.66 and a 200 day simple moving average of $9.86. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80. The stock has a market cap of $47.29 billion, a PE ratio of 30.72, a PEG ratio of 2.82 and a beta of 0.25.

Haleon (NYSE:HLN) last released its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion. On average, research analysts forecast that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The business also recently announced a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be paid a $0.1166 dividend. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

Analysts Set New Price Targets

A number of research firms have issued reports on HLN. HSBC restated a “hold” rating on shares of Haleon in a report on Wednesday. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Finally, Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Five investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Haleon presently has a consensus rating of “Moderate Buy” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.